Skip Navigation Links
   
Skip Navigation Links
   

GI - Pancreatic Cancer


MATCH: Molecular analysis for therapy choice. Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors or lymphoma.  EAY131 (NCT02465050)  (MBMC Contact: Henry Robinson 314-996-5865)

Preoperative extended chemotherapy versus chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas 
A021501 (NCT02839343)  (MBMC Contact:  Henry Robinson 314-996-5865)

Randomized phase II study of 2nd line FOLFIRI versus modified FOLFIRI with PARP inhibitor ABT-888 (veliparib) in metastatic pancreatic cancer 
S1513 (NCT02890355) (MBMC Contact:  Henry Robinson 314-996-5865)

A randomized phase II study of perioperative mFOLFIRINOX versus Gemcitabine/NAB-paclitaxel as therapy for resectable pancreatic adenocarcinoma 
S1505 (NCT02562716)  (MBMC Contact:  Henry Robinson 314-996-5865) 


A phase III trial evaluating adjuvant gemcitabine or combination chemotherapy* followed by chemotherapy or radiation therapy plus capecitabine in resected pancreatic adenocarcinoma.  *Up to 3 months of chemotherapy is allowed prior to registration.   RTOG 0848 (clinicaltrials.gov link has incorrect information)  (MBMC Contact: Henry Robinson 314-996-5865)  (Open at MBMC - RT credentialing required for affiliate sites prior to patient registration)

Phase II study of MLN0128 (TAK-228) in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET)  EA2161 (NCT02893930) (MBMC Contact:  Henry Robinson 314-996-5865)

 
 

All contents 2007 Heartland Cancer Research St. Louis, MO. All rights reserved. Privacy Policy